Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 448 / Drugs : 436 - (DrugBank : 104) / Drug target genes : 68 - Drug target pathways : 185

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

0.005% lacripep
   TearSolutions, Inc.
      2017   Phase 1/Phase 2   NCT03226444   United States
0.01% lacripep
   TearSolutions, Inc.
      2017   Phase 1/Phase 2   NCT03226444   United States
0.02% FM, SH, 0.05% CSA
   Jinyang Li
      2013   -   NCT02147509   China
0.02% FM, SH, AS
   Jinyang Li
      2013   -   NCT02147509   China
0.02% FM, SH, tbcl
   Jinyang Li
      2013   -   NCT02147509   China
0.05% cyclosporine EYE drops
   Peking University First Hospital
      2022   Phase 4   ChiCTR2500099615   China
   Tianjin Eye Hospital
      2024   -   NCT07171710   China
   Tongji Hospital (Tongji Medical College), Huazhong University of Science and Technology
      2021   Phase 4   ChiCTR2500111481   China
0.9% sodium chloride
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom
   The First Affiliated Hospital of Xiamen University
      2025   -   ChiCTR2500099859   China
11C-MET PET/CT imaging
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom
13-valent pneumococcal conjugate vaccine
   Region Skane
      2016   Phase 4   NCT03762824   -
1643368-58-4
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
18F-FDG PET/CT imaging
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom
23-valent pneumococcal polysaccharide vaccine
   Region Skane
      2016   Phase 4   NCT03762824   -
552-02
   Parion Sciences
      2009   Phase 2   NCT00852839   United States
68GA-fapi
   Peking Union Medical College Hospital
      2024   Phase 1/Phase 2   NCT07062523   China
68GA-P16-093
   Peking Union Medical College Hospital
      2023   Phase 1/Phase 2   NCT06049368   -
Abatacept
   Bristol-Myers Squibb
      2016   Phase 3   NCT02915159   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Puerto Rico;Sweden;United States
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb K.K.
      2017   Phase 3   JPRN-jRCT2080223466   Argentina, Brazil, Canada;Asia except Japan;Czech Republic, Germany, France;Europe;Italy, Mexico, Puerto Rico;Japan;Japan, Korea, US, Australia;North America;Oceania;South America;Sweden
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
Abatacept SC
   University Medical Center Groningen
      2014   Phase 3   NCT02067910   Netherlands
ABBV-323
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-003131-31-NL   Netherlands
Acetylcysteine
   The Fourth Affiliated Hospital of Nanjing Medical University
      2023   Phase 4   ChiCTR2300071950   China
Acoltremon
   Center For Sight
      2025   Phase 4   NCT07277257   United States
Acupuncture combined with oral hydroxychloroquine sulfate tablets
   Senyue Zhang
      2023   -   NCT06432101   China
Acupuncture GB20 or GB20 plus BL2
   Taipei Veterans General Hospital, Taiwan
      2025   -   NCT06771427   Taiwan
Acycloguanosine
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Allogeneic adipose tissue-derived mesenchymal stem cells expanded
   Rigshospitalet-Glostrup
      2020   Phase 2   EUCTR2020-002804-38-DK   Denmark
Allogeneic adipose tissue-derived stromal/stem cells
   Rigshospitalet-Glostrup
      2020   Phase 2   EUCTR2020-002804-38-DK   Denmark
Allogeneic NK cells
   Artiva Biotherapeutics, Inc.
      2025   Phase 2   NCT06991114   Brazil;Bulgaria;France;Germany;Italy;Poland;Portugal;Romania;Serbia;Spain;United States
Allogeneic stem cell transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States
AMG 557/MEDI5872
   MedImmune LLC
      2015   Phase 2   NCT02334306   France;Sweden;United Kingdom;United States
   MedImmune, LLC
      2015   Phase 2   EUCTR2014-003896-41-GB   France;Sweden;United Kingdom;United States
Anifrolumab
   University Medical Center Groningen
      2022   Phase 2   NCT05383677   Netherlands
   University Medical Centre Groningen
      2022   Phase 2   EUCTR2022-000609-28-NL   Netherlands
ANTI-CD19 CAR T cell therapy
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06828042   China
ANTI-CD19 CAR-T cells
   Peking University Third Hospital
      2025   Phase 1/Phase 2   NCT06821659   -
ANTI-CD19 IL-10/IL15 CAR-NK
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2025   -   NCT06614270   China
ANTI-CD19-CAR-T cells
   First Affiliated Hospital of Wenzhou Medical University
      2024   Early Phase 1   NCT06420154   China
ANTI-CD19-CD3E-CAR-T cells
   Shanghai Changzheng Hospital
      2024   -   NCT06373081   China
ANTI-CD19/bcma U CAR T cells
   Changhai Hospital
      2026   Early Phase 1   NCT07246096   China
ANTI-CD28DAB
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
ANTI-pandemic H1n1 influenza vaccine
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil
Arava
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
ARGX-113
   argenx BV
      2023   Phase 2   EUCTR2021-005911-30-BE   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
      2022   Phase 2   EUCTR2021-005911-30-NL   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
Artificial saliva
   Pontificia Universidad Catolica de Chile
      2006   Phase 4   NCT00438048   Chile
Ascs
   Rigshospitalet, Denmark
      2020   Phase 2   NCT04615455   Denmark
ASP5502
   Astellas Pharma Global Development, Inc.
      2024   Phase 1   NCT06544642   United States
Assigned interventions CD19/bcma CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05085431   China
Autologous CD19-bcma DUAL-target CAR T-cell therapy
   Beijing Boren Hospital
      2025   Phase 1   NCT07361094   China
Autologous serum
   GIANCARLO FATOBENE
      2025   Phase 2   NCT07014059   Brazil
   Hospital Nacional Profesor Alejandro Posadas
      2017   Phase 4   NCT03608761   Argentina
   Instituto de Oftalmología Fundación Conde de Valenciana
      2024   Phase 3   NCT06931041   Mexico
   Pontificia Universidad Catolica de Chile
      2018   Phase 3   NCT03436576   Chile
Autologous serum tears combined with 0.05% cyclosporin EYE drop
   Chengdu University of Traditional Chinese Medicine
      2022   -   NCT06013436   China
Autologous stem cell transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States
AúN NO establecido
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004387-54-ES   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
Baminercept
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 2   NCT01552681   United States
Baricitinib
   Peking Union Medical College Hospital
      2022   Phase 2   NCT05016297   China
Baricitinib 2 MG
   Peking Union Medical College Hospital
      2020   Phase 1/Phase 2   NCT04916756   China
BCMA-CD19 CAR-T therapy
   Peking University People's Hospital
      2024   Phase 2   NCT06794008   China
Bcma/CD19 CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06428188   China
Bcma/CD70-targetd CAR-T
   Chongqing Precision Biotech Co., Ltd
      2025   Phase 1   NCT07184450   China
BCT301
   Peking University Third Hospital
      2025   Early Phase 1   NCT07301164   -
Belimumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2009-015978-35-FR   France
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 2   NCT01160666   France
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline
      2016   Phase 2   NCT02631538   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06410833   China
Benlysta - 120 MG - polvere PER concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) 120 MG 1 flaconcino
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Biopsy OF THE labial salivary gland
   University Hospital, Bordeaux
      2020   -   NCT03841318   France
Biospecimen collection
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Blood function test, liver function test, kidney function test, and immune function test
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2021   -   NCT04749875   France
   Centre Hospitalier Régional d'Orléans
      2025   -   NCT06842316   France
   Juntendo University, Sclool of Medicine
      2014   -   JPRN-UMIN000012844   Japan
   University Hospital, Bordeaux
      2020   -   NCT03841318   France
   University Hospital, Limoges
      2010   -   NCT01081184   France
Blood sample analysis
   Tianjin Eye Hospital
      2020   -   NCT05633524   China
Blood samples
   Centre Hospitalier Universitaire de Saint Etienne
      2018   -   NCT03003572   France
Blood sampling
   Department of Gastroenterology and Hepatology,Kyoto University Graduate School of Medicine
      2010   -   JPRN-UMIN000003519   Japan
   University Hospital, Montpellier
      2022   -   NCT05528809   France
Blood, fluid, sells and urine samples
   University Hospital, Brest
      2020   -   NCT04931160   France
BMS-188667
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
BMS-931699
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb
      2016   Phase 2   NCT02843659   Australia;Chile;Colombia;France;Hungary;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb
      2016   Phase 2   NCT02843659   Australia;Chile;Colombia;France;Hungary;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
BMS-986325
   Bristol-Myers Squibb
      2021   Phase 1   NCT04684654   Germany;United States
BMS986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS986195
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
Branebrutinib
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
BRL-301
   Bioray Laboratories
      2023   -   NCT05859997   China
BTK inhibitor
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BUPI5
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark
Bupivacaine
   Hvidovre University Hospital
      2012   Phase 2   NCT01584947   Denmark
Bupivacaine hydrochloride
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark
Bupizenge
   Clinical Research Centre, Hvidovre University Hospital
      2012   Phase 2   EUCTR2011-006196-19-DK   Denmark
Cabozantinib
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Calcium carbonate D
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China
CAR-NK cell
   Bangdong Gong
      2025   Phase 1/Phase 2   NCT06967038   China
Carbomer
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom
Carbomer 974P
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Carbomer GEL/jelly
   Chang Gung Memorial Hospital
      2023   -   NCT06406933   Taiwan
Carboxy methyl cellulose
   Cairo University
      2021   Phase 3   NCT04252209   Egypt
Cathepsin S
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
Cathepsin S inhibitor
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
CD19 or CD19-bcma CAR-T
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06548607   China
CD19 targeted CAR-T cells
   Chongqing Precision Biotech Co., Ltd
      2023   Phase 1   NCT06056921   China
CD19 UCAR-T cells
   Institute of Hematology & Blood Diseases Hospital, China
      2026   -   NCT07212322   China
CD19- bcma CAR-T cells
   Essen Biotech
      2024   Phase 1/Phase 2   NCT06350110   China
CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2025   Phase 1/Phase 2   NCT06947460   China
CDZ173
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2014-004616-12-PL   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-HU   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-DE   Germany;Hungary;Poland
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02775916   Germany;Hungary
Cenegermin
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
Cepharanthine
   Yamanoi Tomoko
      2011   Phase 2-3   JPRN-jRCTs061180072   -
Cevimeline
   Department of Dentistry and Oral Surgery, Tochigi National Hospital
      2008   Phase 1   JPRN-UMIN000000997   Japan
   The Affiliated Huai'an Hospital of Xuzhou Medical University
      2020   Phase 0   ChiCTR2000033420   China
CFZ533
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-001942-20-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-001942-20-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Türkiye;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-SI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2013-004808-19-DE   Germany;Hungary;Switzerland;United Kingdom;United States
      2014   Phase 2   EUCTR2013-004808-19-HU   Germany;Hungary;Switzerland;United Kingdom
      2014   Phase 2   EUCTR2013-004808-19-GB   Germany;Hungary;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT03905525   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
CFZ533 active - cohort 1
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
CFZ533 active - cohort 2
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
CFZ533 active - cohort 3
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
CFZ533 active -cohort 3
   Novartis Pharmaceuticals
      2014   Phase 2   NCT02291029   Germany;Hungary;Switzerland;United Kingdom;United States
Chinese herbal TEA tbdesjs
   Taipei Veterans General Hospital, Taiwan
      2025   -   NCT06771427   Taiwan
Ciclosporin
   Charité Berlin, Department of rheumatology
      -   -   EUCTR2009-013976-38-DE   Germany
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
Citric acid
   Juntendo University
      2025   -   JPRN-UMIN000060736   Japan
   Juntendo university Urayasu Hospital
      2018   -   JPRN-UMIN000053206   Japan
Citric acid based mouthwash
   Grupo de Investigação em Bioquímica e Biologia Oral
      2013   Phase 4   NCT03578900   -
CLN-978
   Cullinan Therapeutics Inc.
      2025   Phase 1   NCT07041099   France;Germany;Italy;United States
CM336
   Keymed Biosciences Co.Ltd
      2026   Phase 1   NCT07642843   China
Comirnaty concentrate FOR dispersion FOR injection
   University Medical Center Groningen
      2021   Phase 4   EUCTR2021-001414-10-NL   Netherlands
Crefmirlimab
   radboudumc
      2023   Phase 2   EUCTR2022-001484-27-NL   Netherlands
Cryostor CS10
   Rigshospitalet, Denmark
      2020   Phase 2   NCT04615455   Denmark
Cyclophosphamide
   Shanghai Chest Hospital
      2025   -   ChiCTR2500112369   China
Cyclosporin
   Hospital Hietzing
      2020   -   NCT04597762   Austria
Cyclosporin A
   National Eye Institute (NEI)
      1997   Phase 2   NCT00001731   United States
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China
Cyclosporine
   Peking University Third Hospital
      2021   -   NCT05605314   China
Cyclosporine 0.09% ophthalmic solution
   Center for Ophthalmic and Vision Research, LLC
      2021   Phase 4   NCT04835623   United States
Cyclosporine A
   Charite University, Berlin, Germany
      2010   Phase 2   NCT01693393   Germany
Cyclosporins
   Pavly Moawd
      2018   Phase 3   NCT03865888   Egypt
Cytokine
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Dazodalibep
   Amgen
      2025   Phase 3   NCT06747949   Argentina;Australia;Belgium;Brazil;Canada;Chile;Croatia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;New Zealand;Peru;Poland;Portugal;Serbia;Slovenia;South Korea;Spain;Taiwan;United Kingdom;United States
      2024   Phase 3   NCT06245408   Argentina;Australia;Belgium;Brazil;Canada;Chile;Croatia;Denmark;France;Germany;Greece;Hungary;Italy;Japan;Mexico;New Zealand;Peru;Poland;Portugal;Puerto Rico;Serbia;Slovenia;South Korea;Spain;Taiwan;United Kingdom;United States
      2024   Phase 3   NCT06104124   Argentina;Australia;Belgium;Brazil;Canada;Chile;Croatia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;New Zealand;Peru;Poland;Portugal;Puerto Rico;Serbia;Slovenia;South Korea;Spain;Taiwan;United Kingdom;United States
   Kawada Ayaka
      2025   Phase 3   JPRN-jRCT2061250001   Asia-Pacific region;Europe;Japan;North, Central and South America
      2024   Phase 3   JPRN-jRCT2061240009   Asia-Pacific region;Europe;Japan;North, Central and South America
      2024   Phase 3   JPRN-jRCT2061230107   Europe;Japan;North, Central and South America;the Asia-Pacific
Dehydroepiandrosterone
   Helsinki University
      2003   Phase 4   NCT00543166   Finland
   National Institute of Dental and Craniofacial Research (NIDCR)
      1997   Phase 2   NCT00001598   United States
   UMC Utrecht
      2000   Phase 2   NCT00391924   Netherlands
Deucravacitinib
   Bristol-Myers Squibb
      2023   Phase 3   NCT05946941   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Peru;Poland;Portugal;Puerto Rico;Romania;South Korea;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
Dexamethasone parotid irrigation
   National Institute of Dental and Craniofacial Research (NIDCR)
      2011   Phase 2   NCT01316770   United States
Diquafosol
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
DNA exome sequencing
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Dornase alfa
   UConn Health
      2011   Phase 1   NCT01357447   United States
Drug: abatacept
   Bristol-Myers Squibb
      2020   Phase 2   NCT04186871   Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   The Cleveland Clinic
      2013   Phase 2   NCT02027298   United States
Efalizumab
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Efgartigimod
   argenx
      2023   Phase 2   NCT06203457   Belgium;Hungary;Poland
      2023   Phase 2   NCT05817669   Belgium;Hungary;Netherlands;Poland
Efgartigimod alfa
   argenx BV
      2023   Phase 2   EUCTR2021-005911-30-BE   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
      2022   Phase 2   EUCTR2021-005911-30-NL   Belgium;Czechia;Germany;Hungary;Netherlands;Poland;Spain
Efgartigimod PH20 SC
   Asahi Yo
      2024   Phase 3   JPRN-jRCT2031240584   (about 38 countries);Asian countries;EU;Japan;U.S.
   argenx
      2025   Phase 3   NCT06684847   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;China;Colombia;Estonia;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Jordan;Lebanon;Lithuania;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Saudi Arabia;Serbia;Slovakia;South Korea;Spain;Sweden;Tunisia;Turkey (Türkiye);United Kingdom;United States
Escherichia coli
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
ESG206
   Shanghai Escugen Biotechnology Co., Ltd
      2026   Phase 2   NCT07375524   China
Estetrol
   Erasmus MC
      2008   -   EUCTR2007-003537-16-NL   Netherlands
Etanercept
   National Institute of Dental and Craniofacial Research (NIDCR)
      1999   Phase 2   NCT00001954   United States
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Evadry
   University Tunis El Manar
      2024   -   NCT06313905   -
Exosome preparation
   Guangdong ProCapZoom Biosciences Co., Ltd.
      2025   Early Phase 1   NCT07192666   -
Filgotinib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
Fluoropyrimidine
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
FMP-30
   University of Miami
      2019   Phase 1   NCT03926286   United States
G1567970
   Galapagos NV
      2021   Phase 2   EUCTR2020-003298-22-HU   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-GR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-FR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-ES   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-DE   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;United Kingdom
GLPG3970
   Galapagos NV
      2021   Phase 2   NCT04700280   France;Germany;Greece;Hungary;Poland;Spain;Ukraine
      2021   Phase 2   EUCTR2020-003298-22-HU   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-GR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-FR   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-ES   France;Germany;Greece;Hungary;Netherlands;Poland;Spain;Ukraine;United Kingdom
      2021   Phase 2   EUCTR2020-003298-22-DE   France;Germany;Greece;Hungary;Poland;Spain;Ukraine;United Kingdom
Glucocorticoid
   Shanghai Chest Hospital
      2025   -   ChiCTR2500112369   China
GS-4059
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
GS-6034
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
GS-9876
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
GSK2618960
   GlaxoSmithKline Research & Development Limited
      2017   Phase 2   EUCTR2016-004258-14-GB   United Kingdom
GSK2618960 2 MG/KG
   GlaxoSmithKline
      2017   Phase 2   NCT03239600   United Kingdom
Heart rate variability
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Herpes zoster vaccine
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
HGS1006, lymphostat-B
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2009-015978-35-FR   France
HGS1006, lymphostat-B, monoclonal ANTI-blys, LSB, benlysta
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
HRIL-2 active
   Peking University People's Hospital
      2015   Phase 2   NCT02464319   China
Hydrocortisone
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands
   Hospital Hietzing
      2020   -   NCT04597762   Austria
Hydrocortisone sodium phosphate
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
Hydroxychloroquine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00632866   France
   Aviation General Hospital
      2022   Phase 1   ChiCTR2300078648   China
   Ege University
      2005   -   NCT00873496   Turkey
   Kanazawa University Graduate School of Medical Science
      2010   -   JPRN-UMIN000004477   Japan
   Peking Union Medical College Hospital
      2022   Phase 2   NCT05016297   China
   Peking University People's Hospital
      2025   Phase 2   NCT06862284   China
   Seoul National University Hospital
      2011   Phase 3   NCT01601028   Korea, Republic of
   Shanghai Tongji Hospital
      2019   Phase 4   ChiCTR1900022696   China
   The First Affiliated Hospital of Nanchang University
      2025   -   ChiCTR2600117190   China
   Tongji Hospital of Tongji University
      2018   -   ChiCTR1800014623   China
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands
   Yueyang Hospital of Integrative Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
      2014   Phase 1 study   ChiCTR-IPR-14005441   -
Hydroxychloroquine 400MG/D
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   France
Hydroxychloroquine sulfate
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   Beijing Hospital
      2023   Phase 4   ChiCTR2300069222   China
   Ningbo Medical Center Lihuili Hospital
      2022   Phase 4   ChiCTR2200057578   China
   Qingwen Tao
      2024   Phase 2   NCT06519617   China
Hydroxychloroquine sulfate tablets
   China-Japan Friendship Hospital
      2022   -   ChiCTR2200061608   China
      2020   -   ChiCTR2000037989   China
   Guang’anmen Hospital,China Academy of Chinese Medical Sciences
      2024   Phase 1   ChiCTR2400079948   China
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04981145   China
HZN-1116
   Amgen
      2024   Phase 2   NCT06312020   Argentina;Austria;Bulgaria;Chile;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Poland;Portugal;Spain;Switzerland;Taiwan;United Kingdom;United States
Ianalumab
   Maruyama Hideki
      2023   Phase 3   JPRN-jRCT2041240054   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Russia;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   JPRN-jRCT2041220098   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Russia;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-IT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2021-005687-22-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-IS   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-GR   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005661-14-PT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-PL   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-LT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-FR   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-DE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-BE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-AT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 2   EUCTR2020-005055-20-FR   France
      2017   Phase 2   EUCTR2016-003292-22-PT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-PL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-NL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-GB   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-DE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-BE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-AT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2025   -   NCT07244289   -
      2023   Phase 3   NCT05985915   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Japan;Lithuania;Mexico;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;South Korea;Spain;Sweden;Taiwan;Turkey (Türkiye);United Kingdom;United States
      2022   Phase 2   NCT05124925   France
Ianalumabproduct code: VAY736pharmaceutical form: solution FOR injection IN PRE-filled syringeinn or proposed INN: ianalumabcas number: 1929549-92-7current sponsor code: VAY736concentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 150-pharmaceutical form OF THE placebo: solution FOR injection IN PRE-filled syringeroute OF administration OF THE placebo: subcutaneous USE
   Novartis Pharma AG
      2022   Phase 3   EUCTR2021-005687-22-FR   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
IBI355
   Innovent Biologics (Suzhou) Co. Ltd.
      2024   Phase 1   NCT06484855   China
Iguratimod
   Chongqing Hospital of Traditional Chinese Medcine
      2019   -   ChiCTR1900024642   China
   Huzhou Third People's Hospital
      2023   Phase 1   ChiCTR2300072206   China
   Jiangsu Simcere Pharmaceutical Co., Ltd.
      2021   Phase 2   NCT04830644   China
   Peking Union Medical College Hospital
      2017   Phase 1/Phase 2   NCT03023592   China
   Shanghai Tongji Hospital
      2019   Phase 4   ChiCTR1900022696   China
   Tianjin Medical University General Hospital
      2019   -   ChiCTR1900021345   China
Iguratimod tablets
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04981145   China
Ikervis
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
Immune checkpoint inhibitors
   Hospital Universitario Araba
      2024   -   NCT07249060   Spain
IMVT-1402
   Immunovant Sciences GmbH
      2025   Phase 2   NCT06979531   Argentina;Brazil;Canada;Chile;Colombia;Germany;Greece;Hungary;Italy;Mexico;Peru;Poland;Romania;Spain;United Kingdom;United States
Inactivated and fragmented influenza vaccine (A / michigan / 45/2015 (H1n1) PDM09-like virus, A / singapore / infimh-16-0019 / 2016 (H3n2) -like virus
   University of Sao Paulo General Hospital
      2018   Phase 4   NCT03540823   Brazil
IND 127861
   radboudumc
      2023   Phase 2   EUCTR2022-001484-27-NL   Netherlands
Inebilizumab
   Nafang Hospital, Southern Medical University
      2025   Phase 4   ChiCTR2500111123   China
Insulin lispro
   Instituto de Oftalmología Fundación Conde de Valenciana
      2024   Phase 3   NCT06931041   Mexico
Ipilimumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Iscalimab
   Maruyama Hideki
      2019   Phase 2   JPRN-jRCT2071200072   Australia;Hungary;Japan
   NOVARTIS PHARMA AG
      2021   Phase 2   EUCTR2020-001942-20-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2022   Phase 2   EUCTR2020-001942-20-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Türkiye;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2020-001942-20-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001942-20-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-SE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-RO   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-NL   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2018-004476-35-GB   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-SI   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-PT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-IT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-HU   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-GR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-FR   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-DE   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004476-35-AT   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Russian Federation;Slovenia;Sweden;Turkey;United Kingdom;United States
   Novartis Pharma. K.K.
      2019   Phase 2   JPRN-jRCT2080224883   Asia except Japan;Europe;Japan;North America;Oceania;South America
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04541589   Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;Portugal;Romania;Russia;South Korea;Sweden;Turkey (Türkiye);United Kingdom;United States
JNJ-80202135
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-FR   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
KCT-0809 ophthalmic solution
   Kissei Pharmaceutical Co., Ltd.
      2016   Phase 3   NCT02503189   Japan
      2016   Phase 3   NCT02503163   Japan
      2015   Phase 3   NCT02503176   Japan
Korean RED ginseng
   Hanyang University
      2019   -   NCT03983408   Korea, Republic of
Lacryvisc
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Lanraplenib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States
Leflunomide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands
Leflunomide 20MG/D
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   France
Leflunomide mylan
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands
Leniolisib
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2014-004616-12-PL   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-HU   Germany;Hungary;Poland
      2016   Phase 2   EUCTR2014-004616-12-DE   Germany;Hungary;Poland
Levocarnitine
   Vanderbilt University Medical Center
      2021   Phase 2   NCT03953703   United States
Levofloxacin
   The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
      2020   Phase 1   ChiCTR2000034924   China
Licorice
   Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037057   China
Limphostat-B
   University of Udine
      2009   Phase 2   NCT01008982   Italy
Liposic
   LanZhou University
      2018   -   NCT03434106   China
   Tung Wah Hospital
      2017   -   NCT03060005   China
LO2A EYE drops
   Ocuwize LTD
      2018   Phase 4   NCT03319420   Israel
LOU064
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2018-004387-54-ES   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 2   EUCTR2018-004387-54-BG   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-HU   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-GB   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DK   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-BE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
LOW-dose interleukin-2
   Peking University People's Hospital
      2022   Phase 1/Phase 2   NCT05605665   China
LY3090106
   Eli Lilly and Company
      2015   Phase 1   NCT02614716   Bulgaria;Georgia;Romania;United States
   Matthew C. Baker
      2021   Phase 2/Phase 3   NCT04563195   United States
LY3361237
   Stanford University
      2025   Phase 2   NCT05781451   -
M281
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-FR   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
Mabthera
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   University of Leeds
      2010   -   EUCTR2010-021430-64-GB   United Kingdom
Mabthera - 1 fiala 500 MG 50 ML
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Maxidex
   Alcon Research
      2008   Phase 4   NCT00631358   Canada
MEDI4920
   Viela Bio, Inc.
      2020   Phase 2   EUCTR2019-002713-19-PL   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-HU   Argentina;China;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-GB   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Turkey;United Kingdom;United States
Methotrexate
   GlaxoSmithKline
      2017   Phase 2   NCT03239600   United Kingdom
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Metilprednisolone
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
MHV370
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2020-004937-19-ES   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-004937-19-HU   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
      2021   Phase 2   EUCTR2020-004937-19-DE   China;Germany;Hungary;Israel;Poland;Spain;Switzerland;Taiwan;United Kingdom
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04988087   China;Germany;Hungary;Poland;Spain;Switzerland;Taiwan;United Kingdom
Micofenolato mofetile
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Mighteaflow
   Augusta University
      2011   Phase 1/Phase 2   NCT01647737   United States
Minibody against CD8 conjugated TO desferrioxamine labeled with zirconium ZR 89
   radboudumc
      2023   Phase 2   EUCTR2022-001484-27-NL   Netherlands
Minor salivary gland (labial) biopsy
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom
Mirabegron
   China Medical University Hospital
      2021   Phase 4   NCT04909255   Taiwan
Mizoribine
   Graduate School of Medicine, Chiba University
      2013   Phase 2   JPRN-UMIN000004237   Japan
MMF discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MMF maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MRI imaging with intravenous contrast with gadoterate meglumine
   GlaxoSmithKline
      2016   -   NCT02899377   United Kingdom
Mrna COVD19 vaccine
   Mayo Clinic
      2021   Early Phase 1   NCT04839315   United States
Mscohi-O lenses
   Guangdong ProCapZoom Biosciences Co., Ltd.
      2025   Early Phase 1   NCT07185139   -
MTS109
   Shanghai Changzheng Hospital
      2026   Early Phase 1   NCT07526350   China
MTX discontinuation
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
MTX maintain
   University of Sao Paulo General Hospital
      2023   Phase 4   NCT05879419   Brazil
Mycophenolate mofetil
   Kaohsiung Medical University
      2016   Phase 2   NCT02691949   -
Mycophenolate mofetil 2000MG/D
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 2   NCT05113004   France
Mycophenolate mofetil teva
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Mycophenolate sodium
   University Hospital Muenster
      2005   Phase 1   NCT00542763   Germany
N-acetylcysteine syrup
   University of Sao Paulo General Hospital
      2021   -   NCT04793646   Brazil
Natural herbs OF coconut, aloe vera, and pepperint
   Cairo University
      2021   Phase 3   NCT04252209   Egypt
Nerve growth factor
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
NGX267
   TorreyPines Therapeutics
      2008   Phase 2   NCT00637793   United States
Nipocalimab
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 2   EUCTR2021-000665-32-IT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen Research & Development, LLC
      2024   Phase 3   NCT06741969   Argentina;Austria;Brazil;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;South Korea;Spain;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
      2021   Phase 2   NCT04968912   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Janssen-Cilag International NV
      2022   Phase 2   EUCTR2021-000665-32-NL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PT   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-PL   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-FR   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-ES   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
      2021   Phase 2   EUCTR2021-000665-32-DE   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Nishikawa Kazuko
      2022   Phase 2   JPRN-jRCT2031210484   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States Of America
   Ohashi Hiroki
      2025   Phase 3   JPRN-jRCT2071240089   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Kingdom Of The Netherlands;Korea Republic Of;Mexico;Norway;Poland;Portugal;Romania;Spain;Switzerland;Taiwan Province Of China;Turkiye;United Kingdom Of Great Britain;United States Of America
Nivolumab
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
NO treatment
   Alcon Research
      2008   Phase 4   NCT00631358   Canada
OL-CD19-GDT
   Beijing GoBroad Hospital
      2025   Phase 1   NCT07167537   China
Olive OIL
   University of Sao Paulo General Hospital
      2010   Phase 4   NCT01850979   Brazil
Omalizumab
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2014   Phase 1   NCT01716312   United States
Omega 3 fatty acid
   Hawler Medical University
      2021   Phase 2/Phase 3   NCT05005806   Iraq
Ophthalmic emulsion
   Allergan
      2001   Phase 3   NCT00025818   United States
Oral microbiome
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Orelabrutinib
   The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
      2026   Phase 2   ChiCTR2600121587   China
Orencia
   Arthritis & Rheumatism Associates, P.C.
      2016   Phase 2   NCT03411850   United States
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   University Medical Center Groningen
      2014   Phase 3   EUCTR2014-000417-31-NL   Netherlands
      2010   Phase 2   EUCTR2009-015558-40-NL   Netherlands
Orencia 125 MG solution FOR injection IN PRE-filled syringe
   Bristol-Myers Squibb International Corporation
      2021   Phase 2   EUCTR2019-002205-22-NL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-PL   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-GB   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-FR   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-ES   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-DE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002205-22-BE   Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
OSE-127
   Institut de Recherches Internationales Servier
      2021   Phase 2   EUCTR2020-001526-59-DE   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-HU   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-GB   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
Oxervate
   DOMPé FARMACEUTICI S.P.A.
      2021   Phase 3   EUCTR2021-003749-39-IT   Italy;United States
Oxybutynin, tolterodine, solifenacin
   China Medical University Hospital
      2021   Phase 4   NCT04909255   Taiwan
P-552
   Parion Sciences
      2010   Phase 1/Phase 2   NCT01369589   United States
Paracetamolo
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Parsaclisib
   Incyte Corporation
      2019   Phase 2   NCT03627065   United States
Pilocarpine
   Oita University Faculty of Medicine
      2013   -   JPRN-UMIN000010796   Japan
   Pontificia Universidad Catolica de Chile
      2006   Phase 4   NCT00438048   Chile
   Teikyo University
      2009   -   JPRN-UMIN000029307   Japan
Pilocarpine hydrochloride
   Department of Pediatrics, Graduate School of Medicine, Chiba Univerity
      2008   -   JPRN-UMIN000001460   Japan
   Federal University of São Paulo
      2005   Phase 3   NCT04470479   Brazil
Plaquenil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
      2022   Phase 2   EUCTR2019-002470-32-NL   Italy;Netherlands;Norway
      2022   Phase 2   EUCTR2019-002470-32-GR   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-NO   Greece;Italy;Netherlands;Norway
      2021   Phase 2   EUCTR2019-002470-32-FR   France;Greece;Italy;Netherlands;Norway
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-005218-38-FR   France
   ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS
      2021   Phase 2   EUCTR2019-002470-32-IT   France;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   UMC Utrecht
      2015   -   EUCTR2014-003140-12-NL   Netherlands
   University Medical Center Utrecht
      2021   Phase 2   EUCTR2020-001933-11-NL   Netherlands
Platinum compound
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Platinum doublet
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States
Prednisone
   Chongqing Hospital of Traditional Chinese Medcine
      2019   -   ChiCTR1900024642   China
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
   Peking University People's Hospital
      2015   Phase 4   NCT02370550   China
   Yueyang Hospital of Integrated Medicine affiliated to Shanghai University of Tradition Chinese Medicine
      2017   -   ChiCTR-INR-16009629   China
Privigen 100 MG/ML, solution pour perfusion
   Hôpitaux Universitaires de Strasbourg
      2019   Phase 3   EUCTR2017-001371-24-FR   France
Privigen® 100MG/ML AT THE dose OF 2G/KG OF body weight
   University Hospital, Strasbourg, France
      2019   Phase 3   NCT03700138   France
Probiotic product - CAP
   Cairo University
      2018   Phase 1/Phase 2   NCT03840538   Egypt
Promestriene vaginal
   University of Sao Paulo General Hospital
      2026   Phase 4   NCT07153276   Brazil
Proteomics
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
PRP injection
   Universidad Nacional de Colombia
      2014   Phase 3   NCT02257957   -
R-2487
   Rise Therapeutics LLC
      2026   Phase 1   NCT06297213   -
Rapamycin
   Peking University People's Hospital
      2022   Phase 1/Phase 2   NCT05605665   China
Raptiva
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 2   NCT00344448   United States
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Ravagalimab
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-003131-31-NL   Netherlands
RC18 160 MG
   RemeGen Co., Ltd.
      2019   Phase 2   NCT04078386   China
RC18 240 MG
   RemeGen Co., Ltd.
      2019   Phase 2   NCT04078386   China
RD06-04 cart cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2024   Early Phase 1   NCT06549296   China
RD06-05 CAR-T cell injection
   Nanjing Bioheng Biotech Co., Ltd.
      2026   Early Phase 1   NCT07596680   China
Rebamipide
   Hospital Nacional Profesor Alejandro Posadas
      2017   Phase 4   NCT03608761   Argentina
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
   Otsuka Pharmaceutical Co., Ltd.
      2005   Phase 2   NCT00233363   Japan
      2005   Phase 2   JPRN-jRCT2080220036   Japan
   Tochigi medical center
      2013   Phase 2   JPRN-UMIN000010710   Japan
   University of Alexandria
      2020   -   NCT01759108   Egypt
Recombinant human proteoglycan 4
   Lubris Bio Pty Ltd
      2025   Phase 2   NCT07118241   Australia
Refresh endura
   Federal University of São Paulo
      2013   Phase 4   NCT02004067   Brazil
Remibrutinib
   Novartis Pharma AG
      2021   Phase 2   EUCTR2018-004387-54-BG   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-GB   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Jordan;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DK   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-DE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004387-54-BE   Australia;Belgium;Brazil;Bulgaria;China;Czechia;Denmark;Estonia;France;Germany;Hungary;Italy;Japan;Lithuania;Netherlands;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04035668   Australia;Belgium;Bulgaria;China;Denmark;Germany;Hungary;Spain;Switzerland;Taiwan;United Kingdom;United States
Restasis
   Federal University of São Paulo
      2013   Phase 4   NCT02004067   Brazil
Rice/turkey free diet (R/TFD) group
   University of Palermo
      2023   -   NCT05644795   Italy
Rituximab
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline
      2016   Phase 2   NCT02631538   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline R&D Ltd
      2017   Phase 2   EUCTR2015-000400-26-GB   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2016   Phase 2   EUCTR2015-000400-26-NO   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-SE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-NL   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-FR   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2015-000400-26-DE   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   GlaxoSmithKline, S.A.
      2015   Phase 2   EUCTR2015-000400-26-ES   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   National Institute of Allergy and Infectious Diseases (NIAID)
      2004   Phase 1   NCT00101829   United States
   Peking Union Medical College Hospital
      2024   Phase 4   NCT06410833   China
   The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
      2026   Phase 2   ChiCTR2600121587   China
   University Medical Centre Groningen
      2006   Phase 1/Phase 2   NCT00363350   Netherlands
   University of Leeds
      2010   -   EUCTR2010-021430-64-GB   United Kingdom
   Yokohama City University Hospital Department of Pediatrics
      2015   -   JPRN-UMIN000018376   Japan
Rituximab, mabthera
   University of Copenhagen
      2007   Phase 2   NCT00426543   Denmark
RNA sequencing
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
RO545-9072/F03
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
RO5459072
   F. Hoffmann-La Roche Ltd
      2016   Phase 2   EUCTR2015-004476-30-PT   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-PL   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-GB   France;Germany;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-FR   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004476-30-DE   France;Germany;Italy;Poland;Portugal;United Kingdom;United States
   Hoffmann-La Roche
      2016   Phase 2   NCT02701985   France;Germany;Poland;Portugal;United Kingdom;United States
RSLV-132
   Resolve Therapeutics
      2024   Phase 2   NCT06440525   United States
      2017   Phase 2   NCT03247686   United Kingdom
   Resolve Therapeutics, LLC
      2016   Phase 2   EUCTR2016-001586-87-GB   United Kingdom
S95011
   Institut de Recherches Internationales Servier
      2021   Phase 2   EUCTR2020-001526-59-DE   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-HU   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-001526-59-GB   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
S95011 concentrate FOR solution FOR infusion
   Institut de Recherches Internationales Servier
      2021   Phase 2   NCT04605978   Australia;Canada;France;Germany;Hungary;Spain;United Kingdom;United States
SA001 high dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of
SA001 LOW dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of
SA001 MID dose
   Samjin Pharmaceutical Co., Ltd.
      2020   Phase 2   NCT05269810   Korea, Republic of
Saline
   Affiliated Stomatological Hospital of Nanjing Medical University
      2021   Phase 4   ChiCTR2100052314   China
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
   The Fourth Affiliated Hospital of Nanjing Medical University
      2023   Phase 4   ChiCTR2300071950   China
   UConn Health
      2011   Phase 1   NCT01357447   United States
Sandimmun optoral
   Charité Berlin, Department of rheumatology
      -   -   EUCTR2009-013976-38-DE   Germany
Saphnelo
   University Medical Centre Groningen
      2022   Phase 2   EUCTR2022-000609-28-NL   Netherlands
SAR441344
   Sanofi
      2020   Phase 2   NCT04572841   Argentina;Belgium;Canada;Chile;France;Germany;Hungary;Korea, Republic of;Mexico;Spain;Taiwan;United States
   Sanofi-Aventis Recherche & Développement
      2020   Phase 2   EUCTR2020-000511-77-HU   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States
      2020   Phase 2   EUCTR2020-000511-77-DE   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States
      2020   Phase 2   EUCTR2020-000511-77-BE   Argentina;Belgium;Canada;France;Germany;Hungary;Korea, Republic of;Mexico;Netherlands;Spain;Taiwan;United States
Schirmer'S test
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
SHJ002
   Sunhawk Vision Biotech, Inc.
      2024   Phase 2   NCT06381986   Taiwan
Sialoendoscopy
   Derk Jan Jager
      2014   -   NCT02112019   Netherlands
Smart plug absorbable lacrimal duct plugs
   Tianjin Eye Hospital
      2024   -   NCT07171710   China
Sodium alginate
   Teikyo University
      2009   -   JPRN-UMIN000029307   Japan
Sodium chloride
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Sodium hyaluronate
   Eye Institute of Xiamen University
      2016   Phase 4 study   ChiCTR-OIB-16007789   China
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
   TRB CHEMEDICA INTERNATIONAL SA
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
   Tongji Hospital (Tongji Medical College), Huazhong University of Science and Technology
      2021   Phase 4   ChiCTR2500111481   China
Softacort
   KH Hietzing, Department of Ophthalmology
      2018   Phase 4   EUCTR2017-004929-33-AT   Austria
Solu medrol - 125 MG/2 ML polvere E solvente PER soluzione iniettabile 1 flacone A doppia camera DA 125 MG/2 ML
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
SOLU-medrol
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
SS-1
   Chang Gung Memorial Hospital
      2014   Phase 2   NCT02110446   Taiwan
   China Medical University Hospital
      2014   Phase 2   NCT02855658   Taiwan
Standard care hyaluronic acid EYE drops
   Universidad Nacional de Colombia
      2014   Phase 3   NCT02257957   -
Standard OF care treatment
   Janssen Research & Development, LLC
      2024   Phase 3   NCT06741969   Argentina;Austria;Brazil;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;South Korea;Spain;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
      2021   Phase 2   NCT04968912   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States
   Nishikawa Kazuko
      2022   Phase 2   JPRN-jRCT2031210484   France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Spain;Taiwan;United States Of America
Sulfate D'hydroxychloroquine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-005218-38-FR   France
SVS20
   TRB CHEMEDICA INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-001708-19-GB   France;United Kingdom
      2007   Phase 3   EUCTR2007-001708-19-FR   France;United Kingdom
Systane ultra UD
   Ocuwize LTD
      2018   Phase 4   NCT03319420   Israel
T cell injection targeting CD19 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2024   Early Phase 1   NCT06417398   -
      2024   -   NCT06361745   China
Tachipirina - 500 MG compresse20 compresse
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Tacrolimus
   Eye Institute of Xiamen University
      2016   Phase 4 study   ChiCTR-OIB-16007789   China
   Pavly Moawd
      2018   Phase 3   NCT03865888   Egypt
   The Eye Hospital of Wenzhou Medical University
      2018   -   ChiCTR-IPR-17013772   China
   University of Sao Paulo General Hospital
      2010   Phase 4   NCT01850979   Brazil
TCM (GAN-LU-YIN)GLY
   Chung Shan Medical University
      2016   Phase 2   NCT04111341   Taiwan
Tears naturale forte
   LanZhou University
      2018   -   NCT03434106   China
   Tung Wah Hospital
      2017   -   NCT03060005   China
Teclistamab
   Peking Union Medical College Hospital
      2026   Phase 4   ChiCTR2600123400   China
Telitacicept
   First Affiliated Hospital of Kunming Medical University
      2025   Phase 4   ChiCTR2500107782   China
   The First Affiliated Hospital of China University of Science and Technology
      2023   Phase 0   ChiCTR2300068254   China
   The First Affiliated Hospital of Nanchang University
      2025   -   ChiCTR2600117190   China
   the First People's Hospital of qinzhou
      2024   -   ChiCTR2400079432   china
Telitacicept 160 MG
   RemeGen Co., Ltd.
      2023   Phase 3   NCT05673993   China
   West China Hospital, Sichuan University
      2026   Phase 4   ChiCTR2600118445   China
Telitacicept 80 MG
   RemeGen Co., Ltd.
      2023   Phase 3   NCT05673993   China
Tetracycline
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Thalidomide
   National Institute of Dental and Craniofacial Research (NIDCR)
      1997   Phase 2   NCT00001599   United States
Thymosin beta 4 EYE drops
   Michigan Cornea Consultants, PC
      2011   Phase 2   NCT01393132   United States
TI-0032-III injection
   Therorna
      2026   Phase 1   NCT07413341   China
Tibulizumab
   Matthew C. Baker
      2021   Phase 2/Phase 3   NCT04563195   United States
Tirabrutinib
   Gilead Sciences
      2017   Phase 2   NCT03100942   Poland;Spain;United Kingdom;United States
   Gilead Sciences, Inc.
      2018   Phase 2   EUCTR2016-003558-34-PL   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-GB   Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003558-34-ES   France;Italy;Poland;Spain;United Kingdom;United States
Tivanisiran sodium ophthalmic solution
   Sylentis, S.A.
      2021   Phase 3   NCT04819269   Spain;United States
Tocilizumab
   University Hospital, Strasbourg, France
      2013   Phase 2/Phase 3   NCT01782235   France
Tofacitinib
   Beijing Hospital
      2023   Phase 4   ChiCTR2300069222   China
   National Institute of Dental and Craniofacial Research (NIDCR)
      2025   Phase 2   NCT07281456   United States
      2021   Phase 1/Phase 2   NCT04496960   United States
   Ningbo Medical Center Lihuili Hospital
      2022   Phase 4   ChiCTR2200057578   China
   Peking University People's Hospital
      2021   Phase 2   NCT05087589   China
Traditional chinese medicine pattern
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Traditional chinese medicine pulse diagnosis
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Traditional chinese medicine tongue diagnosis
   Taipei Veterans General Hospital, Taiwan
      2019   -   NCT03935373   Taiwan
Triamcinolone
   Affiliated Stomatological Hospital of Nanjing Medical University
      2021   Phase 4   ChiCTR2100052314   China
UCB5857
   UCB CELLTECH (UK BRANCH OF UCB PHARMA SA)
      2015   Phase 2   EUCTR2014-004523-51-IT   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   UCB Celltech
      2015   Phase 2   NCT02610543   France;Greece;Italy;Spain;Sweden;United Kingdom
   UCB Celltech, UK
      2017   Phase 2   EUCTR2014-004523-51-GR   France;Greece;Italy;Spain;Sweden;United Kingdom
      2016   Phase 2   EUCTR2014-004523-51-SE   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-004523-51-GB   France;Greece;Italy;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-004523-51-FR   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
      2015   Phase 2   EUCTR2014-004523-51-ES   France;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
Umbilical cord blood CD19-bcma CAR-T cells infusion
   Beijing GoBroad Hospital
      2026   Phase 1/Phase 2   NCT06947473   China
Upadacitinib
   Peking University People's Hospital
      2025   Phase 2   NCT06862284   China
Ustekinumab
   University of Rochester
      2020   Phase 1   NCT04093531   United States
Usual medical management OF patients, additional blood and stool samples FOR biobanking
   Santé Arménie French-Armenian Research Center
      2023   -   NCT05904301   Armenia
Varenicline nasal spray
   University of Pennsylvania
      2023   Phase 4   NCT05700422   United States
VAY736
   NOVARTIS PHARMA AG
      2022   Phase 3   EUCTR2021-005687-22-IT   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-IT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2021-005687-22-RO   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SK   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-SE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-IS   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;Iceland;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-HU   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-GR   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-DE   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005687-22-BG   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Peru;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005661-14-PT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-PL   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-LT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-FR   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-DE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Türkiye;United States
      2022   Phase 3   EUCTR2020-005661-14-BE   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 3   EUCTR2020-005661-14-AT   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Korea, Democratic People's Republic of;Lithuania;Mexico;Poland;Portugal;Singapore;Spain;Turkey;United States
      2022   Phase 2   EUCTR2020-005055-20-FR   France
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-000250-22-DE   Germany
   Novartis Pharmaceuticals
      2023   Phase 3   NCT05985915   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Japan;Lithuania;Mexico;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;South Korea;Spain;Sweden;Taiwan;Turkey (Türkiye);United Kingdom;United States
      2022   Phase 3   NCT05350072   Austria;Belgium;Brazil;Chile;China;Czechia;France;Germany;Guatemala;Lithuania;Mexico;Poland;Portugal;Singapore;South Korea;Spain;Turkey (Türkiye);United States
      2022   Phase 3   NCT05349214   Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   NCT02962895   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2014   Phase 2   NCT02149420   France;Germany;Netherlands;United States
VAY736 antibody
   Novartis Farmacéutica, S.A.
      2017   Phase 2   EUCTR2016-003292-22-ES   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Novartis Pharma AG
      2017   Phase 2   EUCTR2016-003292-22-PT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-PL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-NL   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-HU   Argentina;Austria;Belgium;Bulgaria;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-GB   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-FR   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-DE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-BE   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003292-22-AT   Argentina;Austria;Belgium;Chile;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Taiwan;United Kingdom;United States
VAY736 higher dose
   Novartis Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02495129   Netherlands
VAY736 lower dose
   Novartis Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02495129   Netherlands
Vehicle
   Lubris Bio Pty Ltd
      2024   Phase 1/Phase 2   NCT06520202   Australia
   Sunhawk Vision Biotech, Inc.
      2024   Phase 2   NCT06381986   Taiwan
Vehicle control
   Lubris Bio Pty Ltd
      2025   Phase 2   NCT07118241   Australia
   Michigan Cornea Consultants, PC
      2011   Phase 2   NCT01393132   United States
Vehicle ophthalmic solution
   Sylentis, S.A.
      2021   Phase 3   NCT04819269   Spain;United States
VIB4920
   Amgen
      2019   Phase 2   NCT04129164   Argentina;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States
   VIELABIO Inc.
      2020   Phase 2   EUCTR2019-002713-19-IT   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States
   Viela Bio, Inc.
      2020   Phase 2   EUCTR2019-002713-19-PL   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-HU   Argentina;China;France;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Taiwan;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002713-19-GB   Argentina;China;France;Greece;Hungary;India;Italy;Korea, Republic of;Mexico;Peru;Poland;Turkey;United Kingdom;United States
VIB7734
   Amgen
      2018   Phase 1   NCT03817424   Poland;Spain;United States
Vitamin A
   Keio University School of Medicine
      2014   -   JPRN-UMIN000013234   Japan
Vitamin D3
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02633332   Italy
Water
   Department of Dentistry and Oral Surgery, Tochigi National Hospital
      2008   Phase 1   JPRN-UMIN000000997   Japan
   Guang'anmen Hospital, China Academy of Chinese Medical Sciences
      2024   -   ChiCTR2400093768   China
Wheat/milk free diet (W/MFD) group
   University of Palermo
      2023   -   NCT05644795   Italy
Xeros
   Grupo de Investigação em Bioquímica e Biologia Oral
      2013   Phase 4   NCT03578900   -
Xylitol
   Augusta University
      2011   Phase 1/Phase 2   NCT01647737   United States
Xyzal - 20 compresse RI
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2016   Phase 2   EUCTR2015-000400-26-IT   Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil
YI QI yang YIN decoction
   Qingwen Tao
      2024   Phase 2   NCT06519617   China
Yiqi yangyin formula
   China-Japan Friendship Hospital
      2025   -   NCT07145060   China
YTS109 cell
   Children's Hospital of Fudan University
      2026   Phase 1   NCT07439029   China
   China Immunotech (Beijing) Biotechnology Co., Ltd.
      2025   Phase 1   NCT07236801   China
      2025   Phase 1   NCT07236762   China
      2025   Phase 1   NCT07123519   China
      2025   Phase 1   NCT06978647   China